Stifel Canada Lowers HLS Therapeutics (TSE:HLS) to Hold

Stifel Canada lowered shares of HLS Therapeutics (TSE:HLS) from a buy rating to a hold rating in a report published on Thursday morning, PriceTargets.com reports.

A number of other analysts have also issued reports on HLS. Raymond James dropped their price objective on shares of HLS Therapeutics from C$10.00 to C$9.00 and set a market perform rating on the stock in a research note on Friday, July 28th. Stifel Nicolaus lowered shares of HLS Therapeutics from a buy rating to a hold rating and dropped their price target for the stock from C$12.25 to C$5.00 in a research note on Friday.

HLS Therapeutics Trading Down 6.4 %

Shares of HLS opened at C$4.07 on Thursday. The firm has a 50 day simple moving average of C$4.92 and a 200-day simple moving average of C$5.26. The stock has a market cap of C$131.26 million, a price-to-earnings ratio of -3.67 and a beta of 1.24. The company has a debt-to-equity ratio of 84.42, a current ratio of 1.45 and a quick ratio of 1.01. HLS Therapeutics has a 1-year low of C$3.66 and a 1-year high of C$11.22.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Thursday, August 10th. The company reported C($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.17) by C($0.22). HLS Therapeutics had a negative return on equity of 20.38% and a negative net margin of 41.67%. The business had revenue of C$22.05 million for the quarter, compared to analyst estimates of C$21.17 million. During the same quarter last year, the business earned ($0.36) EPS. Equities analysts forecast that HLS Therapeutics will post -0.12 EPS for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.